Insights from IDWeek 2023
M

IDWeek 2023 Insights: The Commercial Development of Human Derived Intestinal Microbiota for Prevention of Recurrent C. difficile Infection

By Insights from IDWeek 2023 FEATURING Michael Woodworth
By Insights from IDWeek 2023 FEATURING Michael Woodworth
0 views
November 8, 2023
Comments 0
Login to view comments. Click here to Login

Recommended

AUTOPLAY
56:03
McMaster University Department of Medicine

Infectious Disease Update - What’s New in ID?

Feat. A. Kapoor
18:34
Houston Methodist Hospital

Proton Pump Inhibitors: Debunking Media Myths

Feat. C. Kim
23:28
ACG 2023 Conference Coverage

Moderation of the Microbiome and C. difficile Infection: Have We Fin…

Feat. P. Feuerstadt
24:52
Paul Feuerstadt

A Clinician's Guide to the Basics of the Microbiota and FMT for…

16:26
Keck School of Medicine of USC

Harnessing the Microbiome to Treat Gut Disease: Myth or Reality?

Feat. B. Zhang
22:18
DDW 2024 Conference Coverage

AGA Clinical Practice Guideline on Fecal Microbiota–Based Therapies …

Feat. C. Kelly
23:15
Stanford Medicine

C. Difficile Colitis: Management in 2024

Feat. K. Keyashian
20:04
EBMed

Guideline Update: Fecal Microbiota Transplantation for Recurrent C. …

Feat. P. Feuerstadt
16:41
Jacinda Abdul-Mutakabbir

SHEA 2024 Insights: Promoting Pharmacoequity in Antimicrobial Stewar…

34:06
University of Minnesota

Frontline Management of C. difficile in the Clinic

Feat. A. Khoruts
13:02
Stanford Medicine

GI Potpourri Panel Question and Answer (Audio Only)

Feat. M. Hawn, N. Fernandez, S. Singh, K. Keyashian
31:00
Insights from IDWeek 2023

IDWeek 2023 Insights: Nervous System Infections and Mimics

Feat. K. Bloch